Cedric Francois, Apellis CEO
November 4, 2022 10:59 AM EDT
R&D
FDA+

FDA de­lays de­ci­sion for Apel­lis' eye dis­ease drug af­ter biotech sub­mits up­dat­ed da­ta

Max Gelman

Senior Editor

Apel­lis had se­cured a pri­or­i­ty re­view for its ge­o­graph­ic at­ro­phy pro­gram, but it turns out the FDA wants to wait a lit­tle bit longer be­fore …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times